EGFR and lung carcinoma: The activity of the epidermal growth factor receptor (EGFR) is frequently elevated in lung cancer, and inhibition of EGFR through the TKI erlotinib can extend survival in patients with advanced lung cancer refractory to chemotherapy [3].